KR20250022145A - 이나트륨 5,10-메틸렌-(6r)-테트라히드로폴레이트를 포함하는 조성물 - Google Patents

이나트륨 5,10-메틸렌-(6r)-테트라히드로폴레이트를 포함하는 조성물 Download PDF

Info

Publication number
KR20250022145A
KR20250022145A KR1020257000562A KR20257000562A KR20250022145A KR 20250022145 A KR20250022145 A KR 20250022145A KR 1020257000562 A KR1020257000562 A KR 1020257000562A KR 20257000562 A KR20257000562 A KR 20257000562A KR 20250022145 A KR20250022145 A KR 20250022145A
Authority
KR
South Korea
Prior art keywords
methylene
citrate
tetrahydrofolic acid
lyophilized composition
disodium salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257000562A
Other languages
English (en)
Korean (ko)
Inventor
루돌프 모저
비올라 그뢴
토마스 암만
장-피에르 크나프
마리안네 스베르드
Original Assignee
메르크 파텐트 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메르크 파텐트 게엠베하 filed Critical 메르크 파텐트 게엠베하
Publication of KR20250022145A publication Critical patent/KR20250022145A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020257000562A 2022-06-08 2023-06-05 이나트륨 5,10-메틸렌-(6r)-테트라히드로폴레이트를 포함하는 조성물 Pending KR20250022145A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22177932 2022-06-08
EP22177932.5 2022-06-08
PCT/EP2023/064972 WO2023237484A1 (en) 2022-06-08 2023-06-05 Compositions comprising disodium 5,10-methylene-(6r)-tetrahydrofolate

Publications (1)

Publication Number Publication Date
KR20250022145A true KR20250022145A (ko) 2025-02-14

Family

ID=81984853

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020257000562A Pending KR20250022145A (ko) 2022-06-08 2023-06-05 이나트륨 5,10-메틸렌-(6r)-테트라히드로폴레이트를 포함하는 조성물

Country Status (9)

Country Link
US (1) US20250360135A1 (enExample)
EP (1) EP4536187A1 (enExample)
JP (1) JP2025518274A (enExample)
KR (1) KR20250022145A (enExample)
CN (1) CN119365186A (enExample)
AU (1) AU2023282347A1 (enExample)
CA (1) CA3258734A1 (enExample)
IL (1) IL317395A (enExample)
WO (1) WO2023237484A1 (enExample)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU575814B2 (en) 1983-03-03 1988-08-11 Bengt Gustavsson A device for transferring a substance
CH682664A5 (en) * 1991-10-15 1993-10-29 Eprova Ag Stable salts of 5,10-methylene tetrahydrofolate.
CN1122456C (zh) * 1996-01-31 2003-10-01 南亚拉巴马医学科学基金会 含有天然的还原叶酸盐异构体的食品和维生素制品
CH697021A5 (de) * 2003-06-26 2008-03-31 Merck Eprova Ag Stabile pharmazeutische Zusammensetzungen von 5, 10-Methylentetrahydrofolat.
KR20080074201A (ko) 2005-12-02 2008-08-12 어드벤트륵스 파마슈티칼스, 인크. 5,10 메틸렌테트라히드로폴레이트의 안정한 약학 조성물
EP2837631A1 (en) * 2013-08-14 2015-02-18 Merck & Cie New stable salt of 5,10-methylene-(6R)-tetrahydrofolic acid
US10059710B2 (en) * 2016-02-17 2018-08-28 Merck & Cie Stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid
ES2902051T3 (es) * 2017-08-16 2022-03-24 Merck Patent Gmbh Liofilizados estables que contienen ácido 5,10-metilen-(6R)-tetrahidrofólico y un ácido dicarboxílico
CN107892692A (zh) * 2017-12-28 2018-04-10 华东理工大学 (6s)‑5‑甲基四氢叶酸锌盐的制备方法及其应用

Also Published As

Publication number Publication date
CA3258734A1 (en) 2023-12-14
JP2025518274A (ja) 2025-06-12
WO2023237484A1 (en) 2023-12-14
IL317395A (en) 2025-02-01
US20250360135A1 (en) 2025-11-27
CN119365186A (zh) 2025-01-24
EP4536187A1 (en) 2025-04-16
AU2023282347A1 (en) 2025-01-16

Similar Documents

Publication Publication Date Title
US8895557B2 (en) Pharmaceutical formulations of ecteinascidin compounds
EP2991619B1 (en) Stable pharmaceutical composition containing folates
US20160030573A1 (en) Stable pharmaceutical compositions of 5,10-methylenetetrahydrofolate
US20090325978A1 (en) Stable lyophilized preparation
US9301922B1 (en) Stable high strength pharmaceutical composition of levoleucovorin
US20160143911A1 (en) Stable and water soluble pharmaceutical compositions comprising pemetrexed
US20080103121A1 (en) Cephalosporin derivative formulation
KR20080074201A (ko) 5,10 메틸렌테트라히드로폴레이트의 안정한 약학 조성물
US20060063833A1 (en) Ready-to-use oxaliplatin solutions
US20250360135A1 (en) Compositions comprising disodium 5,10-methylene-(6r)-tetrahydrofolate
US20250319022A1 (en) Concentrated solutions comprising sodium 5,10-methylene-(6r)-tetrahydrofolate
US20250319089A1 (en) Stable lyophilisates comprising 5,10-methylene-(6r)-tetrahydrofolic acid
WO2023237480A1 (en) Stable pharmaceutical compositions comprising 5,10-methylene-(6r)-tetrahydrofolic acid and nacl
CN119325373A (zh) 包含5,10-亚甲基-(6r)-四氢叶酸的浓缩溶液
WO2025165852A1 (en) Liquid formulations of lurbinectedin
US8785406B2 (en) Stabilized and lyophilized formulation of anthracycline compounds

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

D16 Fast track examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D16-EXM-PA0302 (AS PROVIDED BY THE NATIONAL OFFICE)

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D16-exm-PA0302